US 9,809,809 B2
Neurotoxins exhibiting shortened biological activity
Michael Schmidt, Potsdam (DE); Jurgen Frevert, Berlin (DE); Fred Hofmann, Potsdam (DE); and Gerhard Groer, Potsdam (DE)
Assigned to MERZ PHARMA GmbH & CO. KGaA, Frankfurt am Main (DE)
Appl. No. 14/356,449
Filed by MERZ PHARMA GmbH & CO. KGaA, Frankfurt am Main (DE)
PCT Filed Nov. 8, 2012, PCT No. PCT/EP2012/072158
§ 371(c)(1), (2) Date May 6, 2014,
PCT Pub. No. WO2013/068476, PCT Pub. Date May 16, 2013.
Claims priority of provisional application 61/628,911, filed on Nov. 9, 2011.
Claims priority of provisional application 61/659,137, filed on Jun. 13, 2012.
Claims priority of application No. 11188440 (EP), filed on Nov. 9, 2011; and application No. 12171801 (EP), filed on Jun. 13, 2012.
Prior Publication US 2014/0308267 A1, Oct. 16, 2014
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/52 (2006.01); C07K 14/47 (2006.01); A61K 38/48 (2006.01)
CPC C12N 9/52 (2013.01) [A61K 38/4893 (2013.01); C07K 14/4746 (2013.01); C12Y 304/24069 (2013.01)] 17 Claims
 
1. A polynucleotide encoding a neurotoxin polypeptide exhibiting a reduced duration of muscle paralysis in a subject, wherein the neurotoxin polypeptide comprises at least one E3 ligase recognition motif in a light chain region of the neurotoxin polypeptide, wherein the E3 ligase recognition motif is a binding motif for the E3 ligase MDM2.